SunFOX project (Senescent Undoing of FOXO4 knock down)
Abstract
This project is funded by the National Center for “Gene Therapy and Drugs based on RNA Technology”, CN3, and it is included into the research activity of the Spoke 4 project – Metabolic and cardiovascular diseases.
In this project, specific ASO/siRNA against FOXO4 will be both selected from literature and de novo developed, by specific in silico pipelines of analysis. The aim is to knockdown the expression of FOXO4. The novel in silico analysis will be validated in vitro. Selected ASO/siRNA will be delivered by ad hoc designed carriers or selected by literature. ASO/siRNA efficacy in i) targeting muscle atrophy, ii) treating atherosclerosis and iii) targeting pulmonary fibrosis, will be tested in cellular models.
Pipeline
-
CLINICAL
NEED -
DISEASES
ANALYSIS - DISCOVERY
-
PRECLINICAL
VALIDATION -
PRECLINICAL
DEVELOPMENT -
CLINICAL
STUDIES
Principal Investigator
Contatto
Team di progetto:
Andrea Claudio Li Greci, PhD
Aree terapeutiche:
Product:
RNA-based Drugs
Collaborazioni:
Gene Therapy and Drugs based on RNA Technology
National Research Counsil
- IGM, Pisa, IT
- IFC, Pavia, IT